drugset / Trial / NCT04305249
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone or in combination with nivolumab in patients with advanced solid tumors and hematological malignancies. The study is composed of two modules: ATG-017 monotherapy (Module A) and ATG-017 in combination with nivolumab (Module B). Both Modules A and B will include Dose Escalation Phase and Dose Expansion Phase.
Timeline
- Start
- 2020-08-15
- Primary completion
- 2024-04-11
- Completion
- 2024-05-24
Outcome
Outcome not reported
Stopped (Business): “The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Subject | TIZATERKIB | Small molecule | 5 mg | Oral |